Gemifloxacin mesylate News : GoldBamboo.com http://goldbamboo.com/ Gemifloxacin mesylate News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped By Gleevec(R) http://goldbamboo.com/news-a213002.html New clinical data presented today demonstrated that Tasigna(R) (nilotinib) eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of adult patients with a form of life-threatening leukemia who developed resistance and/or intolerance to treatment with Gleevec(R) (imatinib mesylate) tablets. [click link for full article] Tue, 26 Dec 2006 08:00 EST Gleevec(R) Demonstrates Highest Five-Year Overall Survival Rate In History Of Treatment For Patients With Chronic Myeloid Leukemia http://goldbamboo.com/news-a210381.html Data published today in the New England Journal of Medicine underpinned Gleevec(R) (imatinib mesylate) tablets as a durable and well-tolerated long-term therapy for newly diagnosed adult patients with a form of blood cancer known as Philadelphia chromosome- positive (Ph+) chronic myeloid leukemia (CML). [click link for full article] Thu, 07 Dec 2006 08:00 EST Interim Analysis Of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels Of HIV Suppression To Boosted Lopinavir http://goldbamboo.com/news-a206688.html Encouraging results from an interim analysis of a new study suggest that the boosted protease inhibitor (PI/r) INVIRASE(R) 500 mg/r (saquinavir mesylate) has the potential to achieve comparable levels of viral suppression to the most commonly used PI, lopinavir/r (Kaletra(R)), with less lipid elevation. [click link for full article] Tue, 14 Nov 2006 08:00 EST Ruboxistaurin Reduced Vision Loss In Patients With Moderate To Severe Non-Proliferative Diabetic Retinopathy In A New Study http://goldbamboo.com/news-a206687.html Eli Lilly and Company (NYSE: LLY) today announced results from a three-year phase 3 clinical trial in which ruboxistaurin mesylate (proposed brand name Arxxant(TM), pronounced ark-ZONT) reduced the risk of sustained moderate vision loss by 40 percent when compared to placebo in patients with moderate to severe non-proliferative diabetic retinopathy (DR). [click link for full article] Tue, 14 Nov 2006 08:00 EST Lilly Announces FDA Requirement Of Additional Clinical Trial Before Ruboxistaurin Could Be Approved For Treatment Of Diabetic Retinopathy http://goldbamboo.com/news-a200753.html Eli Lilly and Company today announced that it is weighing options for the further development of ruboxistaurin mesylate in light of a request by the Food and DrugAdministration (FDA) for an additional, three-year, Phase 3 clinical trial. [click link for full article] Sat, 30 Sep 2006 07:00 EST